Abstract
Although convalescent plasma (CP) transfusion was prioritized among potential Ebola treatments by the World Health Organization, there were concerns on the feasibility of its implementation. We report on the successful organization of donor mobilization and plasma collection as part of the Ebola-Tx clinical trial from November 2014 to July 2015 in Conakry, Guinea. Project implementation registers, tools and reports, mission reports, and minutes of research team meetings were used to reconstruct the sequence of events on how donor mobilization was organized, plasmapheresis was set up, and how effective this approach was in collecting CP. An initial needs assessment of the Guinean National Blood Transfusion Center resulted in targeted training of staff on site, resulting in autonomy and independent production of CP within 3 months. The Conakry Ebola Survivors Association played a direct role in donor mobilization and organization of CP donations. A total of 98 Ebola survivors were screened for plasma donation, of which 84 were found eligible for plasmapheresis. Of these, 26 (30.9%) were excluded. The remaining 58 donors made a total of 90 donations, corresponding to 50.9 L of CP. This sufficed to treat the 99 eligible patients enrolled in the trial. Within a poor resource emergency context, transfusion capacity could be rapidly improved through the strengthening of local capacities and gradual transfer of skills coupled with active involvement of Ebola survivors. However, large-scale plasma collection or multisite studies may require further adaptations of both strategy and logistics. The Ebola-Tx trial was funded by the European Union and others.
Highlights
The present outbreak of Ebola virus disease (EVD) in west Africa is the largest ever recorded.[1]
We report on the successful organization of donor mobilization and plasma collection as part of the Ebola-Tx clinical trial in Donka Hospital, Conakry, Guinea
Tools and reports, mission reports, and minutes of research team meetings were used to reconstruct the sequence of events on how donor mobilization was organized, plasmapheresis capacity was established, and how effective this approach was in collecting convalescent plasma (CP)
Summary
The present outbreak of Ebola virus disease (EVD) in west Africa is the largest ever recorded.[1] In September 2014, the World Health Organization (WHO) prioritized convalescent whole blood (CWB) and convalescent plasma (CP) transfusion among potential Ebola therapies in the hope that they could rapidly be implemented if proven safe and effective.[2] WHO called for proper testing of these therapies in clinical trials rather than compassionate use,[3] and developed an interim CWB and CP guideline for patients with EVD as an empirical treatment during outbreaks.[4]. National blood transfusion services are poorly developed in the affected countries, and plasma collection and processing is not routinely done. This would require the rapid introduction of new technology, which adhered to international standards necessary for a clinical trial, during a medical emergency. The Guinean Ebola context was characterized by community reluctance and mistrust toward official health education EVD messages, aggravated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American Society of Tropical Medicine and Hygiene
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
